FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2918241527> ?p ?o ?g. }

• W2918241527 abstract "Abstract Receptor interacting protein kinase-1 and -3 (RIP1 and RIP3) are essential mediators of cell death processes and participate in inflammatory responses. Our group recently demonstrated that gene deletion of Rip3 or pharmacological inhibition of RIP1 attenuated pathogenesis of abdominal aortic aneurysm (AAA), a life-threatening degenerative vascular disease characterized by depletion of smooth muscle cells (SMCs), inflammation, negative extracellular matrix remodeling, and progressive expansion of aorta. The goal of this study was to develop drug candidates for AAA and other disease conditions involving cell death and inflammation. We screened 1141 kinase inhibitors for their ability to block necroptosis using the RIP1 inhibitor Necrostatin-1s (Nec-1s) as a selection baseline. Positive compounds were further screened for cytotoxicity and virtual binding to RIP3. A cluster of top hits, represented by GSK2593074A (GSK’074), displayed structural similarity to the established RIP3 inhibitor GSK’843. In multiple cell types including mouse SMCs, fibroblasts (L929), bone marrow derived macrophages (BMDM), and human colon epithelial cells (HT29), GSK’074 inhibited necroptosis with an IC50 of ~3 nM. Furthermore, GSK’074, but not Nec-1s, blocked cytokine production by SMCs. Biochemical analyses identified both RIP1 and RIP3 as the biological targets of GSK’074. Unlike GSK’843 which causes profound apoptosis at high doses (>3 µM), GSK’074 showed no detectable cytotoxicity even at 20 µM. Daily intraperitoneal injection of GSK’074 at 0.93 mg/kg significantly attenuated aortic expansion in two mouse models of AAA (calcium phosphate: DMSO 66.06 ± 9.17% vs GSK’074 27.36 ± 8.25%, P < 0.05; Angiotensin II: DMSO 85.39 ± 15.76% vs GSK’074 36.28 ± 5.76%, P < 0.05). Histologically, GSK’074 treatment diminished cell death and macrophage infiltration in aneurysm-prone aortae. Together, our data suggest that GSK’074 represents a new class of necroptosis inhibitors with dual targeting ability to both RIP1 and RIP3. The high potency and minimum cytotoxicity make GSK’074 a desirable drug candidate of pharmacological therapies to attenuate AAA progression and other necroptosis related diseases." @default.
• W2918241527 created "2019-03-11" @default.
• W2918241527 creator A5000603446 @default.
• W2918241527 creator A5004179295 @default.
• W2918241527 creator A5015182615 @default.
• W2918241527 creator A5029003935 @default.
• W2918241527 creator A5029155983 @default.
• W2918241527 creator A5036652821 @default.
• W2918241527 creator A5058601007 @default.
• W2918241527 creator A5063307513 @default.
• W2918241527 creator A5087038090 @default.
• W2918241527 creator A5087354808 @default.
• W2918241527 creator A5090815103 @default.
• W2918241527 date "2019-03-06" @default.
• W2918241527 modified "2023-10-18" @default.
• W2918241527 title "Identification of a novel class of RIP1/RIP3 dual inhibitors that impede cell death and inflammation in mouse abdominal aortic aneurysm models" @default.
• W2918241527 cites W1537667127 @default.
• W2918241527 cites W1803162504 @default.
• W2918241527 cites W1906972812 @default.
• W2918241527 cites W1918712426 @default.
• W2918241527 cites W1968023901 @default.
• W2918241527 cites W1975858576 @default.
• W2918241527 cites W1986283558 @default.
• W2918241527 cites W1987920150 @default.
• W2918241527 cites W1989124918 @default.
• W2918241527 cites W1998983498 @default.
• W2918241527 cites W2010354804 @default.
• W2918241527 cites W2010508038 @default.
• W2918241527 cites W2020154042 @default.
• W2918241527 cites W2038096193 @default.
• W2918241527 cites W2039254613 @default.
• W2918241527 cites W2042421692 @default.
• W2918241527 cites W2046864536 @default.
• W2918241527 cites W2050891951 @default.
• W2918241527 cites W2055063967 @default.
• W2918241527 cites W2057880516 @default.
• W2918241527 cites W2071500926 @default.
• W2918241527 cites W2078141613 @default.
• W2918241527 cites W2080373577 @default.
• W2918241527 cites W2081053802 @default.
• W2918241527 cites W2084414744 @default.
• W2918241527 cites W2090263751 @default.
• W2918241527 cites W2091263717 @default.
• W2918241527 cites W2110796758 @default.
• W2918241527 cites W2124202816 @default.
• W2918241527 cites W2125171421 @default.
• W2918241527 cites W2130776456 @default.
• W2918241527 cites W2158662692 @default.
• W2918241527 cites W2161371655 @default.
• W2918241527 cites W2169820248 @default.
• W2918241527 cites W2178250841 @default.
• W2918241527 cites W2231291760 @default.
• W2918241527 cites W2280294408 @default.
• W2918241527 cites W2291832556 @default.
• W2918241527 cites W231086871 @default.
• W2918241527 cites W2357133200 @default.
• W2918241527 cites W2402118151 @default.
• W2918241527 cites W2410171354 @default.
• W2918241527 cites W2411565536 @default.
• W2918241527 cites W2478800195 @default.
• W2918241527 cites W2581795848 @default.
• W2918241527 cites W2584580415 @default.
• W2918241527 cites W2587053851 @default.
• W2918241527 cites W2609546453 @default.
• W2918241527 cites W2734851839 @default.
• W2918241527 cites W2740713121 @default.
• W2918241527 cites W2791073178 @default.
• W2918241527 cites W2951428751 @default.
• W2918241527 doi "https://doi.org/10.1038/s41419-019-1468-6" @default.
• W2918241527 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6403222" @default.
• W2918241527 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30842407" @default.
• W2918241527 hasPublicationYear "2019" @default.
• W2918241527 type Work @default.
• W2918241527 sameAs 2918241527 @default.
• W2918241527 citedByCount "61" @default.
• W2918241527 countsByYear W29182415272019 @default.
• W2918241527 countsByYear W29182415272020 @default.
• W2918241527 countsByYear W29182415272021 @default.
• W2918241527 countsByYear W29182415272022 @default.
• W2918241527 countsByYear W29182415272023 @default.
• W2918241527 crossrefType "journal-article" @default.
• W2918241527 hasAuthorship W2918241527A5000603446 @default.
• W2918241527 hasAuthorship W2918241527A5004179295 @default.
• W2918241527 hasAuthorship W2918241527A5015182615 @default.
• W2918241527 hasAuthorship W2918241527A5029003935 @default.
• W2918241527 hasAuthorship W2918241527A5029155983 @default.
• W2918241527 hasAuthorship W2918241527A5036652821 @default.
• W2918241527 hasAuthorship W2918241527A5058601007 @default.
• W2918241527 hasAuthorship W2918241527A5063307513 @default.
• W2918241527 hasAuthorship W2918241527A5087038090 @default.
• W2918241527 hasAuthorship W2918241527A5087354808 @default.
• W2918241527 hasAuthorship W2918241527A5090815103 @default.
• W2918241527 hasBestOaLocation W29182415271 @default.
• W2918241527 hasConcept C185592680 @default.
• W2918241527 hasConcept C190283241 @default.
• W2918241527 hasConcept C203014093 @default.
• W2918241527 hasConcept C2776914184 @default.
• W2918241527 hasConcept C31573885 @default.
• W2918241527 hasConcept C502942594 @default.
• W2918241527 hasConcept C55493867 @default.

• next